Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
September 10, 2001
- To Bolster Globalization Based on Past Experiences: Mr Yoshino of Shionogi
September 10, 2001
- BUSINESS NEWS IN BRIEF -1-
September 10, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 10, 2001
- Additional Data Required for Sanwa Kagaku's SNK-860
September 10, 2001
- Kawasumi Potassium Adsorption Filter Recommended for Approval
September 10, 2001
- Toho Ties Up with Yakushin
September 10, 2001
- Banyu, Kyorin, Teijin to Start Immediate PMS for Montelukast, Alendronate
September 10, 2001
- Cerivastatin's Setback to Favor Sankyo's Mevalotin
September 10, 2001
- MEDICAL DEVICE NEWS IN BRIEF
September 10, 2001
- REGULATORY NEWS IN BRIEF -2-
September 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
September 10, 2001
- REGULATORY NEWS IN BRIEF -1-
September 10, 2001
- Sanyo, NEC Tie Up Regarding Medical Information Systems
September 10, 2001
- Mr Hashimoto Stresses Establishing Durable Social Security System
September 10, 2001
- WORLD NEWS IN BRIEF
September 10, 2001
- Healthcare Industry Can Be Driving Power of Economy: METI Minister
September 10, 2001
- Zimmer of US Listed on NYSE
September 3, 2001
- Medical Costs at Medical Institutions Down 1.9%
September 3, 2001
- Toshiba: High-speed Multislice CT Scanners
September 3, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…